PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910